Lbp Am Sa Sells 36,546 Shares of Medtronic PLC $MDT

Lbp Am Sa cut its holdings in Medtronic PLC (NYSE:MDT) by 69.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 16,080 shares of the medical technology company’s stock after selling 36,546 shares during the period. Lbp Am Sa’s holdings in Medtronic were worth $1,531,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Medtronic by 1.5% during the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Medtronic by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after purchasing an additional 310,684 shares during the period. Bank of New York Mellon Corp increased its position in shares of Medtronic by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 21,275,850 shares of the medical technology company’s stock valued at $1,854,616,000 after purchasing an additional 595,549 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Medtronic by 0.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock valued at $2,008,278,000 after buying an additional 98,220 shares during the period. Finally, Invesco Ltd. lifted its position in Medtronic by 3.9% in the second quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after buying an additional 666,557 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $100.71 on Wednesday. The firm has a market cap of $129.12 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 2.65 and a beta of 0.71. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $99.52 and its 200 day moving average is $95.48.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the business earned $1.26 earnings per share. Medtronic’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Analyst Ratings Changes

MDT has been the subject of a number of recent analyst reports. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Morgan Stanley boosted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Robert W. Baird set a $103.00 target price on shares of Medtronic in a research report on Tuesday, December 16th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Fourteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).